Science Matters: Glimmers Of Hope For Treating ALS

Data And Developments In ALS Research

Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.

Science Matters
Updates In ALS Appear At The Annual Meeting Of The American Academy of Neurology

Much of the buzz at the annual meeting of the American Academy of Neurology (AAN) in early May was around competitive drugs for treating spinal muscular atrophy (SMA), including Biogen Inc.’s Spinraza (nusinersen). Biogen also presented late-breaking interim data from a Phase I/II clinical trial of its antisense amyotrophic lateral sclerosis (ALS) drug candidate tofersen (BIIB067). Only 2% or so of the ALS patient population has a mutation in the superoxide dismutase 1 (SOD1) gene, the target of tofersen. But the tofersen data, coupled with the success of Spinraza, which is also an antisense oligonucleotide (ASO) aimed at a gene mutation affecting neurons, are encouraging signs that targeting genetic drivers of ALS with ASOs or other gene-altering drugs could halt progression of several forms of the disease.

The tofersen data, while preliminary, provided assurance that the drug hits its target and is consistent with the belief that...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Innovation

More from In Vivo